Commons, Marty

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases

Phase 4
Completed
Conditions
Prostate Cancer
First Posted Date
2005-10-20
Last Posted Date
2017-02-23
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
150
Registration Number
NCT00242554

Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas

Phase 4
Terminated
Conditions
Acromegaly
Interventions
Drug: Octreotide acetate
First Posted Date
2005-10-20
Last Posted Date
2012-04-26
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
50
Registration Number
NCT00242541
Locations
🇲🇽

Novartis Investigative Site, Mexico City, Mexico

Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer

First Posted Date
2005-10-20
Last Posted Date
2014-05-07
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
522
Registration Number
NCT00242567
Locations
🇹🇭

Novartis Investigative Site, Songkhla, Thailand

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

First Posted Date
2005-10-20
Last Posted Date
2016-03-31
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
111
Registration Number
NCT00242580
Locations
🇺🇸

Novartis Investigational Site, Austin, Texas, United States

Letrozole in the Treatment of Severe and Recurrent Endometriosis

Phase 2
Completed
Conditions
Severe and Recurrent Endometriosis
First Posted Date
2005-10-18
Last Posted Date
2012-04-26
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
40
Registration Number
NCT00240942

Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment

Phase 4
Terminated
Conditions
Metastatic Breast Cancer
First Posted Date
2005-10-18
Last Posted Date
2012-04-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
13
Registration Number
NCT00241046

Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis

Phase 4
Completed
Conditions
Prostate Cancer With Bone Metastasis
Interventions
Drug: zoledronic acid
First Posted Date
2005-10-18
Last Posted Date
2017-03-06
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
148
Registration Number
NCT00241111

Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma

Phase 3
Completed
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Drug: Octreotide
First Posted Date
2005-10-18
Last Posted Date
2016-04-12
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
270
Registration Number
NCT00241020

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Phase 2
Completed
Conditions
Renal Transplantation
First Posted Date
2005-10-17
Last Posted Date
2017-02-23
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
255
Registration Number
NCT00239798

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Phase 3
Completed
Conditions
Renal Transplantation
First Posted Date
2005-10-17
Last Posted Date
2017-08-22
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
684
Registration Number
NCT00239785
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy